within Pharmacolibrary.Drugs.ATC.M;

model M01AB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.6333333333333333,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Sulindac is a non-steroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation associated with conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. It is approved for use in several countries and remains in clinical use.</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers, following single oral dose administration.</p><h4>References</h4><ol><li>N M Davies, M S Watson,Clinical pharmacokinetics of sulindac. A dynamic old drug.,Clinical pharmacokinetics,1997<a href='https://pubmed.ncbi.nlm.nih.gov/9195115/'>https://pubmed.ncbi.nlm.nih.gov/9195115/</a></li><li>Jin Won Sung, Hwi-Yeol Yun, Sunny Park, Young Ju Kim, Jeong Yee, Kyung Eun Lee, Byungjeong Song, Jee Eun Chung, Hye Sun Gwak,Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor.,Pharmaceutical research,2020<a href='https://pubmed.ncbi.nlm.nih.gov/31993760/'>https://pubmed.ncbi.nlm.nih.gov/31993760/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M01AB02;
